Marker combination, method, and system for immune checkpoint PD-1/PD-L1 dynamic monitoring

Abstract

The invention discloses a marker combination, a method and a system for dynamically monitoring an immune checkpoint PD-1 / PD-L1. According to the method, an Opal / TSA multi-label immunofluorescence technology is adopted to simultaneously detect a plurality of markers related to tumor immunity in tumor tissues, and a Vectra automatic multispectral quantitative pathological image analysis system is combined to carry out data processing. The method disclosed by the invention can be used for guiding the actual medication of the tumor immunosuppressor; on the same tissue, different immune detection points and immune cell markers can detect signals, subtyping can be conducted on cells, cells of all phenotypes are obtained, and a theoretical basis is provided for treatment effect judgment of tumorpatients before and after treatment and guidance of tumor immunotherapy. Dynamic detection can be provided for the curative effect of tumor immunotherapy, clinical medication can be better guided, andmore tumor patients can be benefited from immunotherapy; compared with the conventional immunohistochemical detection technology, the detection target is richer and more intuitive.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a marker combination, method and system for dynamic monitoring of immune checkpoint PD-1 / PD-L1. Background technique [0002] In today's society, due to the influence of various factors such as population aging, lifestyle and living environment, cancer has become the focus of the whole society. According to WHO data, 1 / 6 of the population's death worldwide is due to cancer, and 1 / 2 of the population will develop different types of tumors throughout their life cycle. In recent years, as a new revolutionary technology for tumor treatment, immunotherapy, especially immune checkpoint therapy, has developed rapidly. Multiple programmed death receptor / ligand-1 (PD-1 / PD-L1) inhibitors have been used in lung cancer, Clinical approval has been rapidly obtained in more than a dozen malignant tumors such as liver cancer and melanoma. How to improve the efficacy of PD-1 / PD-L1 inhibitor...

AI Technical Summary

Problems solved by technology

In the interpretation of traditional immunohistochemical results, HE stained sections should be observed first to determine the number and location of tumor cells in the section, and then observe PD-L1 immunohistochemical sections under a low-power microscope to determine whether PD-L1 is positive and whether it is positive. Finally, under a high-power microscope, observe the PD-L1-stained tumor cells that meet the requirements and calculate the percentage, but this method often cannot distinguish which cell the positive signal appears in

Moreover, the detection of PD-L1 expression level alone in tumor patients cannot accurately reflect the effect of patients receiving PD-1 / PD-L1 therapy.

Images